ALT
Altimmune, Inc.
$3.12
+0.01 (+0.32%)
At close · Jul 9
Market Cap
$593.15M
Shares
194,474,154
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.12
Open$3.11
Day$3.04–3.15
52W$2.56–6.44
Avg vol 30d4.2M
Short int47.6M · 24.5% float · 8.1d
Short vol62%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−19%
below
Price vs 50-day avg
+8%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+15%
trailing
6-month return
−25%
trailing
YTD return
−14%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
5 of 173 funds reported for Jun 30 · net +316.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
24.49% of float · ▲ +13.6% MoM · 8.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
173 holders — mid 3-yr range
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+105%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-67.5M
Balance sheet
$9.5M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−19%
Bearish
Price vs 50-day avg
+8%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
5 of 173 funds reported for Jun 30 · net +316.3K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
24.49% of float · ▲ +13.6% MoM · 8.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
173 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $3 · 14%
52-wk high $6
vs 200-day avg -19%
vs 50-day avg +8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALT
this stock
Altimmune, Inc.
|
$593.15M | -13.6% | +105.0% | — | 24.5% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +9.5% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +8.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALT | -1.0% | +14.9% | -25.4% | +2.6% | -13.6% |
| SPY | +0.8% | +2.0% | +8.9% | +0.7% | +10.2% |
| vs SPY | -1.8% | +12.9% | -34.3% | +2.0% | -23.8% |